<SEC-DOCUMENT>0001193125-17-191463.txt : 20170602
<SEC-HEADER>0001193125-17-191463.hdr.sgml : 20170602
<ACCEPTANCE-DATETIME>20170601193203
ACCESSION NUMBER:		0001193125-17-191463
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170601
FILED AS OF DATE:		20170602
DATE AS OF CHANGE:		20170601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		17886119

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d405667d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 1, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is
submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 1, 2017 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>PRIMA BIOMED ANNOUNCES FORMATION OF CLINICAL ADVISORY BOARD</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d405667dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g405667ex991pg1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1&nbsp;June 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED ANNOUNCES
FORMATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF CLINICAL ADVISORY BOARD </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">New Clinical Advisory Board comprises team of internationally renowned clinicians </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provides strategic advice for clinical development of lead drug candidate IMP321 in AIPAC metastatic breast cancer trial </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148; or the &#147;Company&#148;) today announced the formation of a Clinical
Advisory Board (CAB) to serve as a strategic resource to the company as it continues to advance the clinical development program and commercialisation path for its lead drug candidate IMP321 for cancer patients worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CAB will advise Prima on the regulatory and clinical development strategy for its Active Immunotherapy PAClitaxel (AIPAC) clinical trial, which is
investigating the safety and efficacy of IMP321 active immunotherapy in combination with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, Chief Scientific Officer&nbsp;&amp; Chief Medical Officer of Prima, said: &#147;Securing such a distinguished group
of medical professionals is a testament to the growing level of support for immuno-oncology product candidates. While the initial focus of the board will be on developing IMP321 in metastatic breast cancer worldwide, it will also advise us on our
other clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The newly formed board will be chaired by Pr. Martine Piccart,
who will be joined by Doctor Luc Dirix, Professor David Cameron, Doctor Samson Fung, and Professor Salah-Eddin <FONT STYLE="white-space:nowrap">Al-Batran.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Professor Martine J. Piccart</B> is professor of oncology at the Universit&eacute; Libre de Bruxelles (ULB) and Head of the medicine department at the
Institute Jules Bordet, in Brussels, Belgium. With a primary interest in breast cancer (BC) and drug development, Prof. Piccart is a leader in international research collaboration and is the <FONT STYLE="white-space:nowrap">co-principal</FONT>
investigator of several large clinical trials, including HERA, MINDACT, and ALTTO. She is <FONT STYLE="white-space:nowrap">co-founder</FONT> and chair of the Breast International Group (BIG) which unites more than 50 BC research groups around the
world. Prof. Piccart is the immediate past president of the European CanCer Organisation (ECCO, 2014-2015). She has also held presidencies of the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for
Medical Oncology (ESMO), and has served on the American Society of Clinical Oncology Board (ASCO). She joined the Board of Directors of the AACR in 2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Doctor Luc Dirix</B> is Head of Medical Oncology at the Oncology Center at AZ Sint-Augustinus Hospital in
Antwerp, Belgium. He is a member of the American Society for Cancer Research, the European Society of Medical Oncology and the European Organization for Research and Treatment of Cancer. He is past-chairman and current Board member of the Belgian
Society of Medical Oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Professor David Cameron</B> is the Clinical Director and Chair of Oncology at The University of Edinburgh Cancer Research
Centre in the UK. He is a member of the American Society of Clinical Oncology&nbsp;&amp; the European Society for Medical Oncology, and is active in a number of clinical trials in breast cancer in the UK and other countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Doctor Samson Fung </B>of Fung Consulting in Germany, provides strategic and operational assistance to pharmaceutical and biotech companies including
Novartis and Bristol-Myers-Squibb. Dr.&nbsp;Fung is the CEO&nbsp;&amp; Managing Director of Volvox Therapeutics and a member of the American Society of Clinical Oncology, the American Society of Clinical Haematology&nbsp;&amp; the German Society of
Pharmaceutical Medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Professor Salah-Eddin <FONT STYLE="white-space:nowrap">Al-Batran</FONT></B> is the Medical Director at the Institute of
Clinical Cancer Research in Frankfurt, Germany. As a haematologist and oncologist, Prof. <FONT STYLE="white-space:nowrap">Al-Batran</FONT> is on the Board of the University Cancer Centre in Frankfurt, and Task Force director for Phase I/II Trials.
He is a member of the German Society of Clinical Oncology, the American Society of Clinical Oncology, and the European Organisation for Research and Treatment of Cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP321 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP321, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> Antigen Presenting Cell (APC) activator based on the immune checkpoint <FONT STYLE="white-space:nowrap">LAG-3,</FONT> represents one of the first proposed active immunotherapy drugs in which
the patient&#146;s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better
anti-tumour CD8 T cell response. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to
leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s
current lead product is IMP321, based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble
<FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed <FONT STYLE="white-space:nowrap">TACTI-mel</FONT> (clinicaltrials.gov identifier <U>NCT 02676869</U>). A number of additional <FONT
STYLE="white-space:nowrap">LAG-3</FONT> products including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima&#146;s pharmaceutical partners. Prima is also developing an agonist of <FONT
STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information
please visit <U>www.primabiomed.com.au</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT STYLE="white-space:nowrap">378-2933;</FONT> <U>mbeck@troutgroup.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105; <U>mgregorowski@citadelmagnus.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g405667ex991pg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g405667ex991pg1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ >0+& P$1  (1 0,1 ?_$ -8  0  !@,! 0
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M ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0
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M;3E]GH2H!UZF4AUH$%QE UBBMI('L3&,D0 @! " $ ( 0 @! " $ ( 0 @!
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M_.EM%1S\%3(&]>V3W/\ K;[??1AM+THW+M$=6NXU;MI_J@.Y=062^V2DN?\
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M7^V*;T=H4XMTKI(\Z?[0]X^WRBZC)Z4M!>C.0((F-1!IK60(@" $ ( 0 @!
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M"!0%"1F=0===1*1U\I0!'EU)F=23[])>J0$ 0Y #.9G*4])Z</"4AY<( CR
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M:? @,U2^,;N&QV&Q*4[<[3CM4UI[V><QV49UE]?Q>"QEIKZ5F:]:1DK-0AY
M<;=;>0K6;:T+3+_$DD?;&Q&;E*BW6NU&@MY*LTT^M4)O/X\![Y>XQ*I*Y123
M79\HJNFE.T@')GX1,><ON'&,LH;JUTKU$]%50<QG%(PG7VVGV"I .I\_</WS
MBM56B?28W>@M#UG(+F1Y'7[#$EU)..]T,YP)$ ( 0 @! " $ ( 0 @! " $
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MP0( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ 0,89^\20BH$ (
M_.>N6 9_9E."[8+F-J4S+G3<\8OM!I,B<ZN@: .D?A">"Q]B6[B;%Z$NN$J=
M]#^E7+^)>'<VAO9=F. O=4<19;[M^IC*OY1Y'TJIW>8I+;X4RL*3J0$N!"IZ
M1I7+L+=(7%..GZ$J>H[6]9=IW(W+<HI?FRC+P3;.0,QS"13YC4:^D3$5N/3N
MV5O.G31>LT;3A<JH*5:[&O6B:R9%1EIRZ2!UD??I%XK=5;E8LW9X:6'TW8]V
MGU5*QL**@9::^,OL,C&O._!.C>CO.?/$0?NQGNUU[K)_]7W<?2(RVKT91]EN
MG<98W%*%$O3TDUM7*"/-1G/PU]47;^)Z#'*;CK]IDY;H6 )2E^T](F*DE1LT
MXVZ2<IMSKT.E$5J>"?'0>W015W;DE2JW=E*F%QE9E\6#W65"$H4$I*4+"A*2
MDA4M3PG.+QW?AM2BMYE7<D]$F^VB*QE*6%!2/A(,YI)0?+B@@@B%N[<M*EIT
M5-59=)KWK4+KK<I+KHOF+K1W6Z4;OSJ.[7>E<2 4KIKI74ZTJ"ICE4P^VL2]
M<6M7\3:;=J[=B_MRIW=!RL5D.59@]W,</A<1!_\ ,L0D^S2F;DQS?_?/%$-I
MQO=_<BTMMI'(U3YC?E,@:'E^2_7/-2T\C'0MY_G=G1'%7U39)GE<=RVY>9A&
M5O$Y'E3CM6&M)OM>X;OLG7OUB6=M#=)OYFSK29_+:KZBEN"&Y3^$?4TQ*AZR
M8Z]OC[BVS[%O&7=Q:JTI\YX/'>7#DIF#W[_#^"^)M2<?3[+IX&SK5W0NM6TN
M)4=U:>YH2$ M73%[)4!<N)4M%.TX09?VA'6PW-+C##O1>C)=:J>.S+RB<DL;
M-N&7W+#?_*NRCZU)&Z;%WD.JBW?*:N=JVXOTOQ/55BJZ1U?A,_1UZ4@F?@([
M"YQ<4QHY1L2H^E/Y#Q^,\D/*>_7\-BLVLR?]I;DO&%39ML[T^]#7(+IM-M_7
MZ@K--<+U;^8?W0E;X2?7'6M<\,VC&F(P=B;IK4I1^0\QC/(GP5NMVL\S"$>A
M.S:GV;#;EA[V+@+(R?84-I) 6[8\O#A(_B+;5;0<\_03&S:YY75+])P$?A=.
M[.3?<SPF:^1:[%MY'G,INM$[MF,%Z7%NG<;WL'>2V#KDC\]P3<.R.'E*@S3V
MVZ-B83J%-53"C(Z</"/283G/PS>C7$6<1;T:E&O?5H\3BO([S/AO2PF,RV]N
M_P!I)>N/J-F6[NR=)M9R?47#.+;S<?J\6>6$#7\7TU2^1PC>L\X>#[CIOWU_
M U=QY'%>4#G-9;5G#X.]1_FWXK^<D;#LW<KZ/;QR!.YYMJED)"+O8+W0JF3+
M4KI%I ]9CMPYC\(7$OTJ*K]5^.P\_C?*]SJP*<[N5;T5]"Y;D_!U\#<F/]77
M37DX2;/O-@;W/(I347IBA7(^::TT\C'6M<5</7J2ABK6Z^M+UG@,;RHYD9?.
M4,5DV/6[K:LSDN])HV;1;L[8W%(-!N)@]7S?A#&5V)PGR^%->5:QT;6;Y1B5
M]QB++>S?C5^BIYO%<*<5X+3BLLQ\([78NI=^Z9%291C]<KEHKY9:L::TUUH7
MY^KY=0LF-IW\,J?>VM/UX_.<MX+'1;4K%]4VVYKUQ1>TNH7_ )2VW!*<T+2K
M_LDQEBX/354ZFC6G&</>C)=JH"YR\=-9>V%Q3C'>AJ,;N06MD?F"4_/A+6?J
MD(K&-R46VJ/N)<U3>6E(!<])2]>GWQ:*E333O(4G)5BG3K5"(5/^K7[IQ5J2
MU4H2I5'/ZN,CKP]8E$;Z6O66T'+F'G%U[6K40Y*.L@E05.1G*%&M8C*,O=.4
M"1 " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( U]NMMEB&\VVN>;3Y_:
MV;SA6XN)WW#<HM;R4J166:_V^HM]8@<X*4NH:?YVU<4.)!\(OOM+0#SS[5_1
MW?>W=LWDO1]4![)L Q7<;,LNVDW,2FG0YE&'9?6,W5%JRFA8FJUY3C=2M=,X
M?C:JFDI<01JF)MSWEIUH@U=N]VZ4=7?<YV/ZU-VJ"GL^UW2+@JK1M+C2VU,Y
M)N'NA6WNIN:\JR%$O^$Q#%"4F@94HN550><A*1$SN2MJJ2:![.IGRI!U( F?
M,^).@XF,<IRDM1)&(!RC,I)D")JMH$*K:!"JV@0JMH$*K:!"JV@0JMH$*K:!
M"JV@0JMH$*K:!"JV@0JMH$*K:!"JV@0JMH$*K:!"JV@0JMH$*K:!"JV@0JMH
M$*K:!"JV@A&*33=420BH$ 0F9@::^G]TH>E5%=-"U55CM5:DIJ[=;ZI*N(J:
M&E?!X@S#K:QJ#&*6'L3;<H0;>V*?K1DL7L1A9;^&NW;<ML).+[XT-,YITN=/
M.X271F6S.W&0*=YN=RNQ6UEXE8DI7SV6&G@HCQYHYF*R#*<;;E9Q5BW.U+6M
MU?,>RR?F5S"X?N*]DN<X^Q=C2C5V4J4V*3:\#K-?NU+T)W]Q;R]C;1:7722L
MV"[7VSIFKCRMTMQ#:/8D1YJ_RPX&Q$-VY@+?H;1]2R_S7^8/+OZKB/$36C1.
MU9GJ[;9HG+>R+T=W[F5CKVY&$+UY46K+';I3I49R/R+[3W!,DGPG*./BN3O"
MMZ/L/$126A*3HME.P^B9/Y[N>F!:_P!1NY?C$GKE8A!]\-W2]M#0F0]@_;9Y
M*_\ 3&_^<VTD'Y:;WC=CNJ9G\*2NE<MJPGSD-(XU[DI@'&N!QEZW+K3EX,^@
MX']H5Q=;W7F>18"X]3E"Y.#:\4=<\S[$>]EJ2I6";Q[?90V)\E+?+=>,=K#I
M-(+S*KC2S)]$><Q?)3.HUE8QMJ\^A2@XOPT'U#*_VA' U]1CG&19C8N4]J4+
MUF<*]2HI'7*]=G'K@LX<^DQ/!\A0@GE59<[M_P QV9XI:N=-;I:>!5.//W>5
M'&%EM1LQGV2_*GI/H&7^=[D=F$5+$8C&863Z)V)RH]E8)UH:)RWMV=:>%H?>
MO'3WG-334Z5+=J<>:M^2,A*1J0;-6U:U#QT23'&Q7 ?%F#GN8C"7/X*WCZ7D
M_F3Y%YW:4\-Q)E]J;_-OS5F=?LSH==[OMAN;CCJJ;(-N,_L=0V2E;5TPW(Z3
ME*?Q3<=MJ6TR G,F4><Q649K@I..(PN)A%;8,^@X#CC@?/()97G&77Z_0OVI
M=FJ6CTF*ALT2W&ZT/4SB3JAZG=0I/L6D*U/H$C&E[<7\)PDKGUDTEVZ#L+$X
M.[HPEV%Z6R$HR?\ );1/2I"Y<BPH&1XC@=1]D4:W72Y*VO3I,J4Y>["=-M-!
M.;'XI^'I])B'.,=,7&78RT876]$)O0]71VEX96&PDG6:0/ ^1\8I6[-[VY2/
M::?P[DKC233KL7SE<VYSE)Y2!J!.7I\O&,L;=6EO1*N#Z-9/D21I$-;K:,,H
M3WO:*@)DZWZ2/$>O[XLWT%96YP][47)O0SD.']1B$JFM>K\/4M++DT!R#3[!
MY><HA-PE6.M,UV[]N#DIM1ZBK;,@  ")C3[YZZG6+-[Z<IT;9@=QRC5RDG3;
MX%R0OY:T<P/Q2'E(3GX2X$Q6S&$*J.A4VZC0=F5^-+RBV7%HS4?$2F9^E7VB
M44M6YV9.XY5WNI&@L'",ZQC%4[?E96-!/(OX1/SD)\/#32498NDJM)]NDK.5
MQ3W);NXNBGKK4N%*\X@#D<=;^*7\MUQ'@/%*@9ZQE<H.XKM&KD=C:]125O#2
M3BX1W7KHDJ^HR.CN]UIU<U-=;G3$2D6+E7MJ$M1(MU")1EN8[$-JDYJFJDG7
MUG/O8'!7=$[%FGV(^MIFP;'N[NE85I59]Q\XM_RQ\*:;);NE $P9<KE8X.68
MCKX/B;.;"W;.)O0I2GM/Y3R&<\ \$YI&N8Y5@;[J],K:Z:5U4UT-Q67K%ZG[
M*A"*#>?,0T)!**BN;K@$RX*%93O%4O7'5M<<<7X=[]G&W$^O3X'DL1R-Y0XJ
M/Z7D6#W7T13B^].OB;#M_7MU94I24[K5=1PY?K+/9JN7I(<HC..C9YF\:6WO
M3Q;?4X0T^!YS%>6KDUB76&4_#BOHW;B?H]K6;$M7<@ZI*4 561XW=PDC6NQ.
MV))(\2JE2PJ1'&-^US:XO@]-R$ELW(H\UC/*GR>OO>A@\5"3Z5B+C\')(V);
M>Z1OS3\C==CFW]P!,E$V^XTBM)3Y?D5Z4IGZC&_^N/B2/O0L2EM<4F>6Q?E!
MY?7F_P +BLQLK8I1DN]U9GE%W4MR&^7ZW;##ZL #F6S<[O2D^S_B/;..G;YO
MX^<%\3"VG.FFC>E].CK.)B/)WP\O9PF:XJ+^M"#IW:3-+7W5+DN7YOL[1E!.
MBK9DZTS (G,5E")&.MA^<ENU;W;^"GO=4DO6>8QGD\O1?Z%G=M/Z]J7R,V;9
MNZ#MU4!*;MMOF%$M0FI5'7VBN;2>!Y>9=,I9F/5&]8YPY5=3>(PUV#3^E#4>
M?Q'E#XHLP<K&<8&]+H3A<B_E-B4'<CV'JI"LMF=VY?B'++25"?3)3%R5/V".
MA:YM<+R_KE=M]NGU'FKWE9YEPDU8>#E%=,KGPT^S>1F%+U_=.52D*7?,AI)R
MFFIQNMYA,^(IU/\ #QCH6>9O"-Z2BK\HK;*+2[SAW_+AS3L2W5A<-<?U+\)/
MN,DHNMSIMK3(9\*8'@:NQWVG2?0"JWD$CT3C?M\?<)79J$<9#>?4W^\>?Q7)
M#FAA&U+*[LZ?0<9/NK5F<6[J>V"N@!I-T\3F0"$5%>*-<CP!35(:(5Z#K'17
M%/#KDE^+M*IQ[G*KF1;59Y)F"[;;KW&;4.[.V=R2E5#N!AM0E?X>3([5S$^0
M2NJ08WEG632>ZL7AV_MKYS@XKA#BK!Z,5E^,MOKLS]="_,YAB]3+Z?([ _/0
M?*O5M<YO*7RZE<YQLK%X22K"]:<?M)',EEF9PT7,-B4UMM3^8NC=VH'I?)JZ
M1Z? M53"]?(27K&6-ZS)55RT_P"&C7>'Q,=,[5Z*Z[<E\A5!X*(E(#TD&?J*
M21$_%M?27H:9@TQ?MU7:J'(.A1(T$N,R ?=K%H>VJQJUV4,?Q8[V[5576<@X
M)RD?9J/?$M./O+06WT_=T]@+B1QG^Z(BXR>@MO+TCY@_8QD=MQ57J(4I/H\2
M/-I.1]FL8T^IEEIUT(<Y_P"[7[C#V^B.CM #@XRE[=?NB-^*TR4J B%$^'VQ
M*<'I4O "9\A_O"+4C])"I#G\-"?(*$_=Q@UN]8;V$>;S!'VQ&O4B$]NCTCF3
MX'U^C]\2U15>L55=:(S]!]T*;=7:BU-%1,^1BM)/2O=*.5.AD.<0?4-Y[&<N
M(]<"P&GB?LU^R)@U"NQ@A+CQUXQ,VI*G0",5 @!"B>M5 ]D12.Q >R%([$![
M(4CL0'LA2.Q >R%([$![(4CL0'LA2.Q >R%([$![(4CL0'LA2.Q >R%([$"!
MD):<?*+*">E)4#=!/T:>G2(<*?FID)UVD.8>45>ATW Y4(<VLN0^OP^^)23:
M3A1#>(\W]W[9QD=N'0D-Y;2)('E#X2>P5?0FT0YM)R$8WN)T?1U?NDU[Q/S3
M]L5K%^[&J#=-9$&?A%XPWE7=2[RN\<0J<_AX?MYQ=VJ*J2(4V^AT.!=$Y)3S
M&? Z?[8HTHNCCIZOW63OP>A2C4X+J$-ZN%"$C\16H-A(XDJ4L@"4&[,56;C'
MMT?*7C"])TA%R;V)LL%?FN'6E*E77*\9M@3/F-POUJHT@#Q)J:MH 1JSQ> @
MJN]8I]M+Y3I6,DSS$QWK&"Q<_LVKDEWJ)JS(^J7IOQ)MQS(M]=IK4&4E3HJ<
M]QQ2VP/Q<S;%P>7,>4M8Y]_B7A[#:;^,P\4M?M+Y*GK,IY4\S<_=,ER#-<3]
MG#7?EBCK+D_=?Z",46MJJW^L=X=1,%&+V;),C2H@D2346NT/TTS+Q6(XN(YB
M<&8>K>-MRI]&K/H.5^5GG]FDU!<-8^Q7IO15J/?)KTZ#2E][W_0Y:V5N6NZ[
MEY,I,^06K JJF0YY2<O%;;2 KP)3')O<V.#[<:V;EV[+9&'RGT' ^1WGMBIQ
MCB</@,/;ETSQ"=/X,4V:.JN_WT]C(;92T>S^Z;^.*=J!=[Z^[86:ZB9%+4*I
M5T=D16NFL4]6!M"PM]KE0I2A,I /GY<ZLA_$12PF(=O>:<JJJZ-$>WP/H,/V
M?',)Y7/%RSS*5C4E2THWG654FG.E%TZ:.K76>^,?:C_/T0 @*(2'E#5I6L"0
M\A '!2 HSY0>'HX11VX2E5QJ^V@T[6B 003Y3X3\)Q=MPI\.OIZ.HJDWKU$4
MHXSD)2Y2  0/=$UD].\U^6PLJ1U=)*=I:=Y)0\RT^E4^9#[:74&?&:5I4#"Y
M&W>ANW8PFOK17RF2-Z];:E9E*,EL;7J9@M^VHVTR9"T9!MW@MZ2XDA8NN)V&
MX<_-^+F-50NJ,_7'.OY1E6*A\/%82S*'V8T[J'=RWB[BS)GO91F>8867]EB+
MMO\ FR1UIRKMV]&68../W?I]P5BH<)4IZPTU;C2BM:IJ5R6"MH&03Q_#'$Q/
M O!^-;^/E^&5?HQ5?4>_RKS <Z,GI^%XDS2271=NNYWU=?$TI>^T!T4W8.FC
MP[+,=<<!Y#8\UNZ&VB>!0W<OS &0\"3'G;W*#@>ZGNV+D);5+5W(]]E_G#Y[
M8*GQ\QLXF*IHN6DTUVIIZ>DT=?NQ]L-6K*L=W4W1Q] )+;%4C';XT@:_"5/6
MZE>6D'S5../>Y(\.7']SB<1%;-%/$^AX'SV<PL.D\;E&4WYTTO[V#?<WI])J
MF]=C!D-.KQKJ#?#R02PS>\&:^6H^ =>H+ZD(!\TM>R./?Y%V(IO!X^2ZI6T_
M'>5#V. \_>,E<3S;ANU%?V.+FE_%E;?\]G7?)>S!U.VAQ2L;R?;+*V4**FD"
M[W2R/NHF9!Q-RH5-(<(U_&0.$>:Q7)OBG#S<,-=L8BTM4FXVWV4T]]3Z1DWG
MGY>X^"_UC!XO 3Z526(KUII1IV4--W?M9]:5J4KDVTM]V*)R5:<ML%4%\OBC
MYE8PHD^'".5/E9QC!.4<-&=%T3BT>]P_G Y$XO=M_P"J8F$Y:_B8:[%+TJN@
MU!E71CU3X/SG(MC<\80V#SO4%K%YIP )E0>M+E:D@R\XXES@;BS#3D[^!NI)
M:U1I?RM)[++^?_)[.VL/EV?824VUHEOP;;Z%O06GH6GTFF:S#,SLY+%VP_*K
M6XB:5HN&/76E4E2>((>I$E,I>/&.'>R?-K$W&[A[O;NT7>FSW=CB?AW'8;XF
M#QF%G!ZG\6*;]#D6A3+]-I44U0P0M/\ G,NMG7A,+0#QC5^!?@FIPDGZ6=/#
M06*MUPTH3CMC.#];*T%+BOA6A2O!/.GG2/ 2G,1AW''3)-)F.]&>';4O:?51
M]]"XLIY29D&:1X\/=PE%I-4TM)&MN3?M;J3[2O9$T+E(GP ]4'*"AO5JNK3Z
MC2O05M[]QK=>QE73CST^(Z'3T3]\5MW83VFM&Y:N.EJOIU%V820"==>'],9'
M&5=&L78.&F;C1=95HTU_JB]N,TZRU&A=;N/=BFZ%R1^%'J3]PC,].LQ:4^DO
M+'!$"DM*J]97MJ""09>$B//V0K76:TE5:=5"X,<3Z@?;Y^N)3:U:C2:5:=!<
M6R?AU/\ $.)X:QT(4<5V$EX1^!,M!Z.$_.%%4T[S:G5:RY,$\G-,S/CXPBXZ
M5*&]IVFG<C:E)*<6Y4UIT+NTX 0D_P ? 2TGZ^$XQW'+7"VEZ=)JWK=I*D:Q
M?UO:*YLM:'E'PD:<L]3I^*7&-NS?DU\.:='TOVO UYRN*&Y;5MI]23[R]4ZF
MY@$ \P &FGAX><97*#5-&[U*AAA&2>].$8M=*TLNS"T!02H R'PIEIPEZ1&.
M,+6]5.5%M*7I[^JY/=[67-M*$JF$)YM.502)CVRF(ZSO7FJ;T/XJ9R[L9U]A
M*?VJ/UEW9?*5)/,X#J)I6M,B/2DCSBRQF(W5'VVELDTO0JZ#!.WAIQH[-GXG
M2]R.GP+Q3UU2D)^76UC:O[E55)E(Z$%+H\HV+>,Q.[HG<CU*3^<Y][+<MQ,-
MR_A\,].MVH-]^Z9'2Y7DM" *7)+_ $Q09H53WBX-R(.DN6H TC?LYIF&'5+6
M(OJNR<E\IS9<(<*7+=+N!PDIM]-F#_X:F3T6\.ZM"9T>X>8,2 ^$Y!7K&@/\
M#KCC9'[XW+6?YO:7L8S$Q[)OY6<N[R_X+O2<;N69?*/]S'U[ID+'4EO?1R^1
MN;E"E)^$!^I8J!,3F)5-.L>CRC/'BK/+'MK&XE_:>\NZIR\9R@Y<XBW666X;
M?;_,ANOO5"K_ .K7J#8F4;AUQY?X*BW6:HGKI,B@U'NC+'CSB!--8N5/L)'+
M?(?EE>T/ -2?1OR^26HG?]:/4/3D'_6="N4I)>QRU.S/A,AEN?-Y1G_6%Q''
MVOQ"=.IF"?EYY9RBT\&XZ-:G<KXME6GKLZB::1<ON,OST >Q2B )'D6'D$'U
MQA7-+B12JI0DNN)SWY:^64TFHXV+>RXOF?B7)KN';\4I27Z'!J] DE7-::RG
M)GXGY5:D#V1L+FUQ&EILX:76TZLC_:IR_G[4<7F,8O4E.#IWP]9<VNY3NXR#
M]1A6!U9'%0-[9/L":[E5]D9ES@X@BMYX3#OTLU)^4O@AR;CF.:16S[E^.ZBI
M'<]W$:U=VUPMX<"6[C?&2>'@M;P3[S&6WSBS-P_2L#8=WJFTO4S4GY1.&I.M
MC.<=&/UK5M^*:*EONDYBD'YNTN/+E/1K([BUH/+YE$\1.-JWSBNI?>X"U3JN
M/^B:TO)]EEQ_HV>XA+KL0_IHGH[K5S:4$U6S%&K^U\C+W4?[I<LRR?:!&5<X
MZ.BP,:?WC_HF&YY.K37W.>R_A894\+M2ZM=URW*$JC9FXMZC5C+*1SW)=M31
M/ME%_P!<L(Z9X*L>JZ_E@:=WR=7U'[G.[;N="_#:^^\7.F[KF%<W_%[294R!
MJI;5[L[LAX\J9-<Q'IE%X\YLNE.ES"7(PV[^]X47J.?>\GG$D(-V,SPLITU.
M&Z^]3D7ICNM[0JE]3M_G].#Q*$6>HY?8BL23&?\ 6]P]739N_P 67KJ<>7E#
MYB?_ $\3@7L]NG9T:"\-=U;I]6!]18=PZ29D>>RT[H''@6JL@GRCH+G!PPHK
M3>6C2OAR?C4P?[0^:KU3R[=Z'^(CIZJ;NCM+U3=TWI?<D'7,^IS_ !<V(U#D
MO,DMU!!/JB5S:X2:KOXFO]T_E9KR\I/-V+HK>7-?_P!4?F+B.Z'TG_#\R_9H
MW,\',*N8X_X%J$9(\UN$:IN>)_PI&O/RG<X8O1A\$UU8JW\Q/3W0>D@\<JRA
M'A)>'74:^1.HG&PN:G!K6B[>4NNV_G,+\J?.5>[@L++LQ%OY28.Y]TA%02K-
M<@:)/\>(W@"?I(:4(G]:?!O3?N1[;?[K,4_*KSICICEUN7V;]I_*3T]SGH],
MPK<*Z(/CSXG?M/\ =HU"+?K2X+IIQ3]-N7[QC7E:YVO5E%?^M:_IDQ/<WZ."
M)_\ ,VJ'^+%LA'_L$HA<T^!VZ1Q;K]B17_:QSR6O)I?XUC_,(_\ F<]&8,E[
MINH/AS8MDHGYRE;3PC87,K@MJOXO^3+YBO\ M<YX+7DTF_[ZQ_F$1W..BXZJ
MW<2T.'\S&<F2)^O\KB'S*X*3_P"[_DR^8G_:SSV?NY%=<=OQ;/\ FC_S.NBD
M"9WDI?\ ^=R;_P"U07,O@K_S/Y,OF(_VL\]__17?\2Q_FD#W/>B<"9WEI0!_
M^NY,?NM)C)^LK@MZL:OXLOEB/]K//?\ ]%=_Q+/^:<!W0.B4SEO-2F7'_P .
M9./OM(G$?K)X+_\ -CW/^B6CY5^?$M*R&Z_^I9_S2G/=)Z( 2#O,S,&7_P"+
MY7+RF#^3:B#YE<%TK^-3]#_HD_[5N?/_ *&[_B6?\TIW.ZAT/MF1WB"O2G%L
MHE]MI'&,3YF<%K_\O^1+YB\/*GSYN.G^A75_U;/^8R2KNL=#R)RW<<7(3DG%
MLE)^VVB(_6=P4EO?B_Y$C-'RF<^VZ?Z'<]-ZPO\ [A0.]V?H<:!)W2N*Y<0W
MAV2J/_T\#[8Q_K2X(_\ +=?L2^8SKRC<_'I_T1T_O['^84#G=UZ'4 J&XU^=
M$Y M85?U!6DSRSI1P]43+FCP6E_W4O1;E7Q-B/D_Y\M;SRFVEUXBTE_.+:YW
MANAY!(&;9>Y+_N\"OJ@?4?EIC ^:W!?1?O/LMOYT;MKR9\^+VK+\+'MQ5KY&
MRVO]Y7HC944C)-P'M.+.WUW5+_?=01&M/F[P;";C\3$/_IR-I>2GGK3VL-EL
M7L>+A7U&.5_>MZ,Z<E-*]N?72T3\K!JEDK]7SJK72(_7#PE;5(ROO_I2-W">
M1_G?B5)RAEEM1_\ VHNOIW3"KEWR.ENF4!18=NY<2)Z(L5MHQ+62IU%Q2=?5
M&M?YS<.12^!&_<V^S*--FVM3H6?(CSJNRI*YE<(__P!$7_PF#7+OR;+,D_E6
MRNYU<$GX?JKCCU!S^4R*I^7NC1O<ZLIA&MC#797.N32/0X+R!<RKM%C\QRZS
M]EJYZJ&"5_?SQM*2;9TY9(Z03I<<ZM=,2/"9IK562!]L:4N>&&H_AX&3GT5N
MM*O\0];A/V>N:W%3&\16;<J?FX53[OOD837=_G(2HBV],]J0G7E57;DU2E:>
M8I\83X>'"-=\[[M&U@(I]=Z3_P" [UC]G;A6JW^*9I]6!C\N(,4KN_ONBL$4
M'3U@;1F9&LR[(:@ #A,,TE+S:^J-5\]L?_ZZS3^\?]$W;/[/'A^+IB>)L;./
MU,+;AXNY,Q>K[]G4(\A:*'939^C5(\BW:[,:Q2>,IC\TIT&7VQHRYSYW.3G'
M X%)O153;IUO>5>MT1Z#!?L]>7Z5,9GF=-?56%T]]IO3L;KUFJ[WWQ^LVX<_
MY5:]H<>F5!(I\5N%R4!,I$_S"[.(F)3XQKSYQ\5.5;<<+;A]&-NJ[W*IZ3#?
ML_N3EGVL1C\ZOR71*=J-?XL$NXUO<.\CU[UW/\O<?#;<%"030;<6%LIGQY%O
MJJ)$>$P8Y>*YK\98B:E&[;MI*E(QHGUZ&SU&!\D7(;"4^)A,9>IT3Q$ZOTQW
M4NPP6Y]UCKVNH4E6_-RMW,-3:<:Q2B _PE-G=6DZ^!TC5ES,XRNJDL5**VQ2
M7[IZ?#>4'R]X?3#(?B2^OB;K\'5>BK-2Y%UZ]:&2(<;O/4UNVIAT%*F;?DCE
MH0H*!$B+0U;SR:ZZ^7E'(Q/&?%5ZLIYCBF]BE1>L]ME7E\Y+9118'A7)Y4U.
MY9MW)?RXM'7R_P"ZNZ.4%Q>2;G[B7];A*EF[YOD]>%$F?Q"IN:P?MCF7,]SF
M_%J[CL6V^CXDDO!Z?2>UP7+#EQE\E=PF1Y-8FOHX*PI>B2MZ*& /UERJ)_/N
M-QJ.8DJ^HN-94\WI(=>7..3<NX^Y-.5^]N_;E\YZ-99EN%DHX*Q;MV]D817J
M5"E+84"I24D :S2#.<I3F)F<1?C/>3@XS[5\K-ZPHV%]U!07U73U:2 02/*9
MG*7NE[HSQ5J<=V]14ZJF66(N5K!NO3[3?K(I1RGFF ?0GW&<XC=MP=+;=.K0
M87"W<>_<W=_[-?&A*,_G)'@?1I($F<I<)ZP<_;3W[G;5U6CHZNCL+I0H]"[C
M]*V/WN?S"B $ ( 0 @! " $ ( 0 @! " .)3,_T11P4IIO4AXG#DXD) ).L^
M)'G,2(C-+<I2*I768]UUWDE4XAM0G(CQE,J,O00>,$TEH2;Z- DIS]ZB[*E)
M56FW5PE76^BK!K,55,P^DCA+E>0X.$8Y0C<]]0]*1EM3O676W.XGU2DO4S#K
MMM-MA?4*;O&W>%7)"Q)0JL9LSDYSG-7TG,>,:5[*\MOIJ_A[$TU]%>NAW,'Q
M3Q-E[K@,PQEI_5O7$N[>H:+R3H5Z4,I4\Y<MD\09>?)^8]:F*FTNDJ,RI)M]
M13A!F? :1YW$\"\*8S3>P4%78Z'N,HYW<U<BI_IV<8C1]-1G_.3\?2:?KNUK
MTB5O-\G#L@M1(D#;<KN2.7CP%1]1PGXQR,3RKX*Q,:/#7(.GYLSWEOS7\Z(-
M?%Q^&OQHE]YAK?1UQ47XFK[YV@=@:P+./YAN'CY,^5+E;07= \92J*5DD3],
M<:?);A.2I9>)M[/;KX'K,#YT.:.'488W#Y9?MQUI6=QOTILU5<>S;9_YALN]
M-U;F26TW3':1P)/A-5+5(7I(1S;_ "4PJ>[A,9)6OK+3Z3V&$\[^:-)8W(L/
MO]+C<U^"-9WOM [K4:'E8_N?AEWD/Y35?072W..2_A*TIJ&T$^<Q'!O<D\TA
MIPV*M2[4T>NRWSK<.R5,PRW%67]16Y^+:?@:5O';$ZL+2XH4=@Q>^,@'^;;L
MGI&5J G(!JK0VN7EXQQ+_*CC+#M[L+5ZWT;K2:[:ZZGLL+YN^66+2]O%V;K]
M[XMG0NQQ\3!+ET(]55G05O[3W2I2G4_EM=;J^<I#0-U(6H^/ 1JW>6G&=JT[
MLL&]U+HE%ONJ>NP7F)Y0YA&DLWM0NM?GPG!+TR5#6][V$WLQ9!5?=JLZMZ6]
M%.+Q^N>:!F?XV&W4R$><O\.YYAYJW>PE]2;^A+UTH>KP?,G@#,85PF<Y=*NK
M[Z"KXF N62_4KJFJVRWBE6C12*BTU[!20=>8N4R )2\XT[V79AAW2[8O+^"S
MMV,ZRC%1;PV,PMR--<;D'\I,;/REE+@4A9  0I*DK/G\) 4)>F-7<<??]GMT
M&=2A<=;<HR[&GZM!<&5))2#.9! $C.<S+64HV+=R$8I-Z]6Q]A?X5V*K.,DM
MO[Q<4?-Y0 "!K(GV>N4O3*+JY!RW8NKZFC0O:9Z-?Y;=!<F2X$@%0T(G*4M3
M%E1:9-:37N1GNU2;[-/J+JV5$@G7DU'[^$72WM1H36_H;2EUNGK+FSH!/0'4
M^L:B*_$MVY>V]!3<:=%1LNC2Y'X=%) .H'HE&TH*[&MK2NGJ,=QM1::=2ZM.
MI("^*DZ'3QXQ969O0J5-!QDUH3T]3^8O+3H7RF12L)$]9CV1N& KTNI$OB^+
MC[3XZ^8@:TK4ZU6DK$/$)21]FGN.IC-"Y!*DM91VKFPJ$U*N$R/<KT>(BSNP
M;T,CX-S8<C4&7Q+/CP$ID:2TE!SBM;)^#<V$CYVI*00?$SG/T2X"(E=C):-8
M^%<V%*MXS45'29GIX>'EPC 9(6I*>\Z4H43ZTG4@R\-):Z>GAI%9>Z^PV&69
M]X*4.8<H29#B9Z^<HT4FU5%5:DDGHUEK?=2HD GEGY>F)JVJ([,52"746EYU
M*4JG/CIIXS]<)32BETDZBU/$*G+\,I\)3(/AI&%NNHVK45*TJEN=6I(!!]?L
M\/5(165$JF6QJ9:'Q-)4?Q: '3C V5"4I.*UE$I:0F9,Y#66NL_NC'>=+;J9
M;=J<9IO4BW.N)',#XCR_;C&DC;@O:]):G24DJ!4$S$O7+W09M0:6LM=024C7
M3F^V1E$(W-5.M%N)2==>/E,RD/3 %N> 2$D)DK61E+S)F)ZSC%*[*+ZC;M3O
MJ"W7'=Z-!;GUKD #(\3( 3UEK/UQ2L;C^\K0S14G'[Q)RVIT\"B<*#Z53F2
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M2QQ@#DGC[#]XB&9+?22ZC\(]?]$5>HS0]XH5<#[/O$5,KU,X18P" $ <'?\
M+7_AE+V_UP>HM#2RWQ4S'Z6\?OT_F $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
M " $ ( 0 @! " $ ( 0 @! "0\H:M0HA " $->AZ@(BB B02G&TJ\"/42/ \
M916D8NKJDMA.])1]G62#2,+3RJ0%CQ"_C'HXI(BT;T9>RF_XJ,2@Z[RE.+^K
M)KY2VU&,V"L'+662T50_]9ME%4DS\R]3+,8)X/#W&Y2A:D]KA&OJ-RQCL?A]
M%B_?BO[R:?K,7N&T^V5T2I%PV^Q"J2KFGSXW:4DSG/XFZ-"IF-3$9+EN(GOW
ML/AGHI[B^8[>$XQXMP2?X;,\?%;/C3[O>-:W;I/Z?[TI2ZK;.QL*5,%5 :VW
M\9:I^CJ& "):&.=B^#>'\?3\18A&2_Y7L=]-9Z##<W.9&7T5C-+[A_:2<_74
MP*MZ#^GFK4I;-AR*WK/#Z'*KJE"3YA%4Y5-Z>J.;=Y=<+RCN_#NK^&_F9Z;"
M^87FCAJ-8NQ<:Z)68OQHC#Z_MX;)U/,:6\Y[1+E)/_O>AK$(4?#E?M14H ^D
M:1R)\K>'97?BPGB8)=#DFO5I]9Z/#>:#F'9I^(MY?=>QV=WQ4O$U[=.VIC+Z
MUJM.Z60T22#RIK[%;J[AP22W4T?O CGXCE1EE^=</B[L>IH]'A?-EQ/;5,3E
MN!FNI33]#<F815]LZ[)G^7;JT3DB0GZW&*AE)]"OIZ]V4_.4:%_DW&<=&/EH
M6C1IJ=S!^;2U&5<7DMQNNN-Y+N3,$NG;3W:;*ORS-L'N"4J)2E]%XHEN#P!_
MX9] CBXGE!GST6K^'G':TTWVT=*GJL'YL>$,12.99=C+*VQ4)/TNJJ:HO';\
MZD[<XLTV/X]>$A2N15MR6D'.$\#R5J*4IYO &<<Z?*_BNU;=B$+4HK52=/$]
M9@O,]RIN;JG+,K<ZZ7<A6/;NIU[C7==T8=3](MPN[3W5Y(TYJ*XV6M)UXI0S
M<3S"7MCG7.7?%>'M4GA=ZZNF,DZGK;'F!Y38I^SF-JW7\Z<)P;[5T4, NO2_
MU$6OF<K=G,Y;2F>K5F??!EX@4OU$P8XESA3BRTI1N8*XNV+?C0[V%YQ<L<2]
MS"YWA97']&5&O\1I&J[SMKN382Y^<[>YE;$H&JZK';NV@>.JU483]L<N.19[
M:NN6(P]WT6Y?,>QP7%_#.*I*SFN!G:>I?'M5]/M&O:QBN8YOJJ*JIE?V'Z1]
ME4O2'&TG3U:1@Q.&Q-J#=RW<BEKK%KUH[UC-<LOR7P,3AYM_1N0?JD6IPJ<3
M)0($A_"1^X&<<U)TU.G8=:-;FF#4NQI^HM;QY5\N@ X3$OO\!%6U'WM!?<O-
M>Z^XMSSBRD Z25Z-9 ^C641O172C<BZQ27O*/RE!4))',9CR\ >/O,7H]W>>
MHWXOV5MH6Q<YD^(\"==./C&I/VKGLZ25I>@I7)J)('@=./BF(3W?9>AF2.A:
M=!:GDJ*1($R5K(>6GA$QT=I:JH4*EJ5H>"= /Z?3%6FW1&:TU'VI:$4#OXR=
M):2,]. BRC*FIU-J#WO:CI11!,B5"?Q2GI(:3E]\8ZMLW=,W1*J+:[*?IF9^
MOF,9))O46GH12.D%"@#,Z:#CX15*FEZC9@Z6DGK+:Y,$Z'A[(.C=3=LU=NO1
M4H5K*@ KPF>$M(O2AD>C64W\2I^9/VF,4C);II)*I3)])BID*&IXK_P?<#$K
M66C[R[2R.?P^W]T7EH[#=*=Q2DB:1,^<IRB$.PI3,DD\?'UG^F+J@*9_\*_\
M'[HC\Y&[:]Q%-3$25,@3(U)]$))MZ#(RD7JHGTD>XG[(B6I&6WTG"*F4XE(/
M'0@'QE]_E%E)MEE*7:4*W5I)&@'A-(G+U\8ENB)<I=A()F9Q0HW4EGQC*M1N
M1]U=A(5^(^S[HDL<8 Y)X^P_>(AF2WTDNH_ /7_1%7J,T/>*%7 ^S[Q%3*]3
M.$6, @! '!W_ "U^K]X@]1:'O%OBIF/TMX_?I_, ( 0 @! " $ ( 0 @! "
M$ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!$IM:@(BK
M>L" HA$ 1($35@:^/[?="K B-(.,CK(^P\(E2HNOM?SD4)+S"'D%#P;<0>*'
M6TK03_A4% Q7VT]#3762M&HL-3B>+UDS5XY8*PG0_4V:W/$^OYM,H_;%;F$P
M6(ANXFU;E%[57UFY8S+,L-*N'Q6(M=4;DDO!F,UNS^U=P"S7;;8/5A8X.XO9
MED^N=(3&E_HF2RK;>&P^[3I@F^\[%KC3C#"K]%S/'P7U;]SU;U# [GTI].EY
M2K\QV:P5PK_&I%E9I5&<]0JC4P4R]$<^_P (\,W-$\%:G771?EX'?R_G!S0R
MZ-,)G>/@_K3W_"2=>QFJ;OV\NE*\E:G-N/RY2^;_ .$7N[T'*#,_ !4N)2->
M$HXTN7'!;;_0X*3==,GH9ZG"^8WG/A*4SJ[-+Z5NUI[?9-=U?:VZ7GROY-+G
M%%S?A^5E+KB43X?Y].YS2],:-_E1PM<K*._%/H3T+L/58'S7\V<)1WKV#O?;
MLZ^W=:,*N/:3Z?ZL$4F7;A6\'F* *ZW5(22.,G*))(]!E'+O<FN%KR]F[?C/
MJET]AZ.SYSN9D**]A\MG!='PFM';6OIUFM+MV<L#>#GY)O)E=&I4RC\PLEOK
MDI]$FZFF,O9&C^I3+HQ<+>,NQ;Z'%/UGIL#YVL^C!+'Y-A[LML;TH+^9)^)K
MJN[-EU;D+;OE2K*E  5N*O-"7][Y%<Y*?HCD7^2$TW\+,$EUP?R,]#9\[]N#
M3N</SKT[F)3:_C6S#;AV;=SFN=5NW@PJK,R4MU%GO5.HGP^)"5B9]<<^[R2S
M.,:V,;9NRV.+7RGH<+YXN&6ZX[),;7JN6I?\-365Z[1/4K1EPVV];?7I "@G
MY5UJZ%2Y#3X:FE^$D_=&M+DWQ&HO[S#M]6\OG]1Z##>=KE]<DOBX#'VM.EUB
MZ+IT)JIJ:[=L#K%MJ5_3X'9;LB7_ ,NRNU*42G^X^NG4)STCB2Y1<5P=':5-
M.G>J>WP?FRY,9C%_B,=?P^K7;FW73L3-95_;RZR:#F4[LC?WTS)G15MIJAZ@
MEJN43'/ERVXPB]V."O-+I]E^-3TV%\S/(S$.ES.;,8TUSA=7@E\AA59T2=65
M(I7SMAMQ%!$^;Z>SFH">769^2ZJ8E&*]P7QA8A26"Q%%]6-/6>CPG/ODGC/9
MP7$666^VXT^Z23-9WWIVWYL(6;QL]N-0?+)"PO%+LX$I])9IW!KZXX5WA3BN
MU-W;F%Q.Y]E?.>IP'-KE?=@HVN(\KN2>I*^D_5Z]!J>Y8EEMJ*_S+%,EH2@R
M4FLL5TIBCT'YE($B7KC2O8?%V/8Q%J]!_7C2IZ2QQ7PQF%'@\5A\374X78RI
MVZ3%G4.MJD\TZQ/4!UEYHZGA): 9B-62T;S:U].@]#AY1G#>MM.#5=#T4*1Y
M:0V3/3A/4<=)Z@<)Q6FAO8;"TKV=+_+I+8X^VD$<R/P*U*P/ 2$YZS]&L(M-
MZ->LR0MW'))190C^:)S&AD.4SX^) UE&33):4Z&\[<UK3)<B/M \![SX12JK
M2JJ5W9:FFF4%4=1\0.H U,N'AI%M6@K5UI1U*1P2;7J/PGQUX1$?>-ZTI;JT
M,M\CIK(>?@1Y1ET&6+KJ(*$AQ'$?MZ>,4G313U,RP5*DM7PB?'66A3]NL42J
M98IR="G4253\(RI)+K,J22H4KW%/J/WQ66HK/428H8];H2UCX3Z?]L9DGNUZ
M*;4;D4U%:'J),C$56TFJ$C^QA5$K21 D?9_1$,RVTNNO8_F*5QPJ!20-#H1^
MQBFDVE;W=.GN*=7X3[/O$ ]1+BYAH]@B"! '!W_+7ZOWB#U%H>\6^*F8_2WC
M]^G\P @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0
M @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 E/C "0\A[HFNBG0*"%13100J^@
M4$5:3TO6!%JZ*= ZA(>0]T1Z$11#V"+;SK7I%$M0(G%7IUDD.4>0_?[X)4U:
M!1$90J^EMBB(2'&0]T2G0"0B/2^]BFT2U!\O3$U=:U8T>D@4)4)*2%#R(!'N
M,5<5+WDF2M#JM#+75V2RU@Y:RT6NJ29S%3;Z1\>T.LKG.,-S#8>Y_66[;77&
M+]:-JWF6889UL8B_;?U9SCZFC%ZS;+;>X3^NV_PVKF)*^HQBS.3GQF31$F-6
M[EF7WDE>P^'E%;;<?F-ZWQ)Q#:H[6/QJ?5?NU_GF(5?3KL17*4JNV>VVJBHD
M_P [#+*X=?,&CD?=&*YP_P /XF&Y<PN&<?[N*]2.OAN8?'6$_P"VSG,[=-E^
MZO\ B,.NO1ITK7Q*TW'87;1PK!"E-8Q04:Y*$B4FG:;D8T[G!O#%R.X\)A]Q
M_41Z##\[.;.#CNX?B'-*5_Y\WZVS4M\[9W13>P2]LC8Z-1)FJV5ETMRB3XI^
MGJPF<SI&DN7?"#]G\%;2ZJ+]X[>!\R7.G+Y5LY[BKC_M6Y+Q6GT&KKIV@>B.
MY\RDX9EEK69ZVO-;NRA,_)#OSTZ1R9\J>#YRD_@WM+T_>M?(>YP/G/YXX&VK
M;QF"N)=,L-&7BW4P.L[*?2'4*4NDK]T:"?X?EY8FHY?*7U% Y.7ICG7.4'!^
M^]U8NGVZKOT'?L>>/G1::E<_TFXNO#T]4D8E6=C7IGJ5*-/N#NY2),^7EN5C
M>Y3+C_.LZIRC2N<F.')RW[-_$P6S0Z>EG?PWGYYKVZ1O9?D]U;=RY&OH5RB,
M#NO8<VE=4M5CWPW!H^8S3]?:<?K0CT$-L4_-IZ!&G=Y)97.*=K&78+L_)G?P
MG[0?CRQHOY#E-Q?:O^IR:\#6ER[!TUJ59^I&H0->07/!6EA'EI3W9KF/GX>B
M-2?(_#)?<XZ;V[R]1Z'#_M#\XDTL?PY@E'^RNRB^NN]6O48?6]A+-P5&AZAL
M:JM!(U>&U].2J7'^7<7I#V<(T[O)3$*/Z/C8.77%_)H/0X?]H;D]$L5P_=C]
MF_'U-&&W#L,[WH"Q0;T[:O @A'U5JR!A2SX#X$K2DF-1\ELVW&X8NT[G0MVF
MGM.Y9_:$\$4W;^1Y@I/I^+;=/1NZ37]P[%?573<ZJ#-]IKD$:)"KC>J12QP3
MHY;UA,_7I&G/DOQ,EHO6)>E'I<O\_G*&]&F.P6;VITZ(6Y)=S3\36MY[+G7%
M:ROZ3']O+ZA$Y*MN=4[9< &G*BLH62#Z"1'/_4_Q?71\&E=IZ/"^>3D/=?WU
MW,K:Z\*]'\M_ET&K+IVINO.@20-C*FO"2J:[;D^,5(4$F1Y0Y<Z=7Q>!D(YT
MN5/&L;CBL'&5'K^(M/72O2>AP_G3Y!XFD8YGB+:K1;V'GXZ>CI,#J.VQUTTI
M4'NFS/%<A,S3N8_5)5*7X"Q?%<PC7N\ <68:7PKN7WG+;%Q:/48/S2<@\=&J
MXAPEN3_YN_!]V[3Q,7KN@OK*MW-]5TV;I33.:6<?75KT\DTC[_,/5.-.[P;Q
M+;:4L!BHU7T4_4=?_<'R1G**L\59:TUT7G'3V-+O,+N?27U16<$W#IYWAIY:
M2_T%D"Y>9_ETBQI&G<X8XDL-_H>)]-ML[>!YR<I,:_T'B++;UQZU^(2\9-=]
M37%SV>W?LRE"[[4;EVSEU4:[!\D82 9S,U6\C0".?<RK.;"WKF&O4ZK<OEHO
M$]?@^,>!L51V,UP#GL6,M/UNA@M?:KO;U*;KK->J-0.HK+/<J,IX&1%32HE[
M8P_A,=1N>'O1AM<'H\6=N&:Y/<BY8;'8)]N(LOU23+$Z]3H6 ZXEHG4AW^6K
M3202HA1(\^$5>&DEO;MUQ^S\YEMXNW-;ROX>XEK^'.+^5^LE"JI2H<CS2AX'
MYJ!ZYB9,8FTNDR_&PV(TVZKO*@/H/ I(X3"VS,_[X,1O1VE_AW*>Z]W:<EJ"
MFED$</-)\1Y$B#::+1BU+2F4,09#]+B/W]NRV'\P ANRV 0W9; (;LM@$-V6
MP"&[+8!#=EL ANRV 0W9; (;LM@$-V6P"&[+8!#=EL ANRV 0W9; (;LM@$-
MV6P"&[+8!#=EL ANRV 0W9; (;LM@$-V6P"&[+8!#=EL ANRV 0W9; (;LM@
M$-V6P"&[+8!#=EL ANRV 0W9; (;LM@$-V6P"&[+8!#=EL ANRV 0W9; (;L
MM@$-V6P"&[+8!#=EL ANRV 0W9; (;LM@$-V6P"&[+8!#=EL ANRV 0W9; (
M;LM@$-V6P"&[+8!#=EL ANRV 0W9; (;LM@$-V6P"&[+8!#=EL ANRV 0W9;
M (;LM@(2B=V6P"(W7L E#=>P$8;LM@(2ANO8!+T1-) 0W9 2ANR EZ(;L@")
M\0#ZQ$;KV AR)\OW?=$[LEJ&@<HE*6GD=?OA20'(G^R!ZA+[HC=>P5 2 ) "
M43NR(='K'(/+[3"D@J+4 D#@"/42/WPI/K)T:^D<H\OOG[XLG-$-)NKUG+6(
M>^W4G02W&FW4E+C:'$GBEQ(6D^L*!$5E#?5)JL28RE#3!M/M+!5XABM?S?78
MOCM;S3YOJ[+;:GFGQYOG4JYSC'+"V9*CMP<>M+YC8ACL=:=;5Z['[,Y+Y3%Z
MW9G:&XA0K]JMN:SF$B:K"<;?)!\"7+:HF-;_ $G+7IEA[-?L)G5PW%?%.#T8
M3,<=:2U;M^['P4C$[ATQ].]Q3RUNQ.TE4DCX@O;_ !CF/J(MJ8U?_C>0:U@<
M*WUVX?T3MV^:/,FQ_59]FZ?5B[_],PRKZ).D6Y@FNZ:-F7>>85S8!CR'-?'G
M:I$D>L&<8Y<,<.W?9GE^&79;A\R.A8YT<W,/)2L\1YPJ;<3=?KDS"KCVW^AN
MZ)6BIZ8=K$!1,S1V5RW*U,S(T%53$3]<<ZYP#P?>=+N M/K3E'PC)+P/3X#S
M*<]<NDIX;B7,-_Z[A=\+D)&#N=I[H!<KJ>O_ .G3&T+IUK4*5N]Y<B@>^8VM
MN3]%_J L.I1SS2) !0!\(UGRQX&WE+\!"OV[G](]"O-WYB5;=K_Y'<H^G\-A
M*]_P#T8CWA^;1 " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
M$ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0
K @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
